Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 2 3Phase 3 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Plasma cell 1Lymphoid 1

Conditions

Vomiting 13Nausea 11Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Multiple Myeloma 2Colorectal Neoplasms 2Colonic Neoplasms 2Radiation Injuries 1Pancreatic Neoplasms 1Pain 1Neoplasms, Germ Cell and Embryonal 1Nausea With Vomiting Chemotherapy-Induced 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Gallbladder Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Bile Duct Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Palonosetron × Clear all
NCT03097588 2021-07-12

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

OHSU Knight Cancer Institute

Phase 2 Completed
43 enrolled 18 charts
Tumor-Agnostic

Neoplasms

NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

University of Kansas Medical Center

Phase 2 Completed
20 enrolled 8 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT01909856 2015-12-04

The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Completed
92 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡